Use of BinaxNOW COVID-19 Antigen (Ag) Test Training for Long Term Care Facilities

Kentucky Department for Public Health and Abbott Laboratories

December 14, 2020
1:00 - 2:15 P.M. (EST)
Abbott BinaxNOW™ COVID-19 Antigen (Ag) Cards

Michelle Moran, Technical Consultant, Abbott Rapid Diagnostics
BinaxNOW™
COVID-19 Ag Card
Overview

Emergency Use Authorization Granted by FDA
Key Points

• The BinaxNOW™ COVID-19 Ag Card is intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.

• Antigen is generally detectable in nasal swabs during the acute phase of infection.

• Negative results from patients with symptom onset beyond seven days, should be treated as presumptive and confirmation with a molecular assay if necessary, for patient management, may be performed.
BinaxNOW™ COVID-19 Ag Card

*Emergency Use Authorization*

The BinaxNOW™ COVID-19 Ag Card is only for use under the Food and Drug Administration’s Emergency Use Authorization

**What is Emergency Use Authorization (EUA)?**

- FDA emergency access mechanism
- Health & Human Services declare when circumstances exist to justify use of diagnostics under EUA for the diagnosis of COVID-19
- It is not full FDA clearance or approval and is temporary, until the declaration is terminated or revoked.
BinaxNOW™ COVID-19 Ag Card

Emergency Use Authorization

Test Site Obligations:

• Notify relevant public health authorities on intent to run test
• Report all results to healthcare providers and include the Healthcare Provider Fact Sheet. Healthcare providers to include Patient Fact Sheet with results
• Utilize product as outlined in the BinaxNOW COVID-19 Ag Card Instructions for Use
• Ensure all operators are trained to perform and interpret the test
• Have process in place for reporting test result to Healthcare Providers & relevant public health authorities
• Per Product Insert: Collect performance data and report any significant deviations from the product performance characteristics via email to FDA/HHS and to Abbott Technical Support
• Retain all records associated with EUA until otherwise directed by FDA
BinaxNOW™ COVID-19 Ag Card
Technical Overview
# BinaxNOW™ COVID-19 Ag Card

## Product Overview

<table>
<thead>
<tr>
<th>Test Summary</th>
<th>Rapid lateral flow immunoassay for the qualitative detection of SARS-CoV-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testing Environment</td>
<td>Point of Care settings with a CLIA Certificate of Waiver, Compliance or Accreditation</td>
</tr>
<tr>
<td>Specimen Type</td>
<td>Direct nasal swab</td>
</tr>
</tbody>
</table>
| Time to Result | Results visually read at 15 minutes  
*Results should not be read after 30 minutes* |
| Waste Disposal | All components should be discarded as Biohazard Waste |
| PPE for Specimen Collection & Handling | Refer to CDC Guidelines for collecting, handling and testing clinical specimens (link in Product Insert) |
Reagent and Materials

Materials Provided:
- 40 Test Cards
- Extraction Reagent
- Patient Collection Nasal Swabs
- Positive Control Swab
- Blank Nasal Swab for Negative Control
- Product Insert
- Procedure Card
- Healthcare Provider & Patient COVID-19 Fact Sheets

Storage & Stability:
- Store kit at 2-30°C
- Ensure all test components are at room temperature before use
- Stable until the expiration date marked on the outer packaging

Materials Required but not Provided:
- Clock, timer or stopwatch

Optional Materials:
- Plastic Transport Tube
Quality Control

Internal Procedural Controls:

• BinaxNOW™ COVID-19 Ag Card has built-in procedural controls
• In an untested card there will be a blue line at the Control Line position
• In a valid, tested device, the blue line washes away and a pink/purple line appears, confirming that the sample has flowed through the test strip and the reagents are working

Note: If the blue line is not present at the Control Line position prior to running the test, do not use and discard
When is Quality Control Required?

• External Positive & Negative Controls:

• Good laboratory practice suggests the use of positive and negative controls to ensure that test reagents are working properly and that the test is correctly performed

• BinaxNOW™ COVID-19 Ag Card kits contain a positive control swab and sterile swabs that can be used as a negative control

• Required Frequency:
  • New shipments received
  • Untrained operators
  • Conforming with local, state, and/or federal regulations, accrediting groups, or lab’s standard QC procedures.

Note: If correct results are not obtained, contact the Abbott Technical Services Team at 1-800-257-9525 between 8 a.m. and 8 p.m. EST Monday-Friday before testing patient specimens
Nasal Swab Sample Collection

Only the swab provided in the kit is to be used for nasal swab collection

- Insert the nasal swab into the nostril exhibiting the most drainage or congestion
- Using gentle rotation, push the swab until resistance is met
  - At the level of the nasal turbinates
  - Less than one inch into nostril
- Rotate the swab 5 times or more against the nasal wall
- Slowly remove the swab
- Using the same swab, repeat sample collection in the other nostril
Specimen Transport & Storage
Specimen Transport & Storage

For best performance, direct nasal swabs should be tested as soon as possible after collection.

If immediate testing is not possible:

• Do not return the nasal swab to the original paper packaging
• To avoid contamination and preserve sample integrity, place the nasal swab in a clean, unused, tightly capped plastic tube & label with the patient information
• The sample is stable in the plastic tube at room temperature (15-30°C) for up to one (1) hour prior to testing
• If greater than one (1) hour delay occurs, dispose of sample & collect new sample
BinaxNOW™ COVID-19 Ag Card Procedure

Key Points

Prior to Beginning a Test Remember to:

- Ensure all components are at room temperature
- Open test card just prior to use
- Lay test card flat for use
- Ensure Blue Control Line is present
BinaxNOW™ COVID-19 Ag Card Overview

Exterior View

Interior View
BinaxNOW™ COVID-19 Ag Card Test Procedure Overview

1. Add the extraction reagent
2. Insert the sample nasal swab
3. Rotate the nasal swab shaft three times
4. Close the test card; wait 15 minutes
5. Results are read visually

- POSITIVE RESULT
- NEGATIVE RESULT
BinaxNOW™ COVID-19 Ag Card Procedure

Key Points

Step 1:
• Hold extraction reagent bottle **vertically** to ensure adequate volume
• Add 6 drops for a Patient test
• Add 8 drops for a Quality Control test
BinaxNOW™ COVID-19 Ag Card Procedure

Key Points

**Step 2:**
- Insert swab into the bottom hole of the test card
- Firmly push swab upwards until the swab tip is visible in the top hole
BinaxNOW™ COVID-19 Ag Card Procedure
Key Points

**Step 3:**
- Rotate swab shaft *3 times* CLOCKWISE (to the right).
- False negative results can occur if the sample swab is not rotated (twirled) prior to closing the card.
BinaxNOW™ COVID-19 Ag Card Procedure

Key Points

Step 4:
- Peel off adhesive liner from the right edge of the test card
- Close and securely seal the card
- To ensure proper test performance read results at **15 minutes** and not before
- Results should not be read after **30 minutes**
**Result Interpretation**

**Negative**

- **One pink/purple colored line** in the top half of the window, in the Control Line position
- Indicates a negative result & no antigen detected

**Positive**

- **Two pink/purple colored lines** in both the Control & Sample Line position
- Indicates COVID-19 antigen was detected
- Any visible pink/purple line is positive
**Result Interpretation**

**Invalid**

The assay is invalid & should be repeated if:
- Only the Sample Line is present
- No lines are present
- Blue Control Line remains blue

Test should be discarded as Biohazard waste
Near-Patient Workflow: No Swab Transport*
Option A (Collect Patient Swab First, Prior to Test Procedure)

Collect Nasal Swab

**Step 1:** Add the Extraction Reagent

1. Add the extraction reagent

**Step 2:** Insert sample into bottom hole and push firmly upwards so tip is visible in top hole

2. Insert the sample nasal swab

**Step 3:** Rotate (twirl) swab shaft 3 times clockwise (to the right)

3. Rotate the nasal swab shaft three times

**Step 4:** Peel off adhesive liner, close and securely seal card. Read results in the window 15 minutes after closing the card

4. Close the test card; wait 15 minutes

*Swab will not be moved from immediate testing area where sample collection is performed
Near-Patient Workflow:  No Swab Transport*

Option B (Begin Test Procedure, Then Collect Patient Swab)

**Step 1:** Add the Extraction Reagent

**Step 2:** Insert sample into bottom hole and push firmly upwards so tip is visible in top hole

**Step 3:** Rotate (twirl) swab shaft 3 times clockwise (to the right)

**Step 4:** Peel off adhesive liner, close and securely seal card. Read results in the window 15 minutes after closing the card

*Swab will not be moved from immediate testing area where sample collection is performed
Training Toolkit


Six Detailed Training Videos

PowerPoint Training

Helpful Tools & Support Documents

FAQs and Technical Service Contacts
Monday-Friday 8am EST – 8pm EST
1-800-257-9525 or ts.scr@abbott.com
Additional Resources

Ordering Information
• 195-000: BinaxNOW™ COVID-19 Ag Card (40 Tests)
• 195-080: BinaxNOW™ COVID-19 Ag Control Swab Kit (10 Positive Swabs)
• 190-010: Optional COVID-19 Swab Transport Tube Accessory Pack (24 Tubes)

Technical Support Line:
• US +1 800 257 9525, Option 2
  – 8am-8pm EST Monday-Friday
• ts.scr@abbott.com
The BinaxNOW™ COVID-19 Ag Test Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of the presence of Antigen Protein from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

© 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. 120006994-09 11/20
Using the BinaxNOW™ COVID-19 Ag Cards

Doug Thoroughman, PhD, MS, State Epidemiologist (Acting)

CDC Career Epidemiology Field Officer, Kentucky Department for Public Health
Use-Cases for BinaxNOW™ Ag Test Cards

• Three primary scenarios for effective use:
  • Outbreaks
  • Clinical settings
  • “Surveillance” testing

• Each requires different thought processes
  • How often they will be used
  • Who they will be used with
  • What kind of follow-up is needed
Outbreak Scenarios

• Facilities may want to partner with local health department
  • To determine strategies for possible use
  • Coordinate procurement of cards
  • Assist with administration if needed

• Test symptomatic people to get early assessment
  • Speeds up isolation and quarantine decisions

• May test asymptomatic if indicated during outbreaks
  • High likelihood of exposure
  • At least two days have passed since exposure
  • May not have adequate supplies of cards to follow this strategy
  • Not highly recommended
    • Resource intensive
    • Interpretation of results questionable
Interpretation and F/U in Outbreak Settings

- If symptomatic
  - Tests positive: Initiate isolation and contact investigation
  - Tests negative: F/U PCR test to confirm negative
    - Isolate until results received
    - If still negative, quarantine if indicated by situation, consider testing for other illnesses

- If definite exposure but asymptomatic
  - Should be quarantined to start with
  - Positive result indicates infection – Isolate/contact trace - quarantine
  - Negative result – continue with quarantine

- If no exposure identified and asymptomatic
  - Recommend confirming positive result with PCR
  - Negative result taken at face value
Testing of Symptomatic Persons in Clinical Settings

- Can be used in healthcare settings for rapid assessment of COVID-19
  - Must have CLIA certification or waiver
  - FDA Emergency Use Authorization (EUA) approved for individuals suspected of COVID-19
  - Should be used within the first 7 days of symptom onset
- Consider Situation:
  - If NO (or very few) cases identified in community (not likely currently!)
    - Recommend F/U PCR test to confirm a positive test – Isolate until PCR results received
    - Negative result taken at face value – may want to test for Flu, other respiratory pathogens
  - If cases already prevalent in community
    - Positive result would be taken at face value
    - Negative results would be recommended for F/U PCR to confirm if there was a clear exposure UNLESS another etiology for symptoms is identified through testing
    - Negative results do not eliminate the need for quarantine if exposed
“Surveillance Testing” of Defined Populations

Goal is to prevent introduction into facility or patients

• Targeted testing
  • Recommended at least weekly (2X per week ideal)
  • Staff AND incoming inpatients

• If staff or incoming persons are asymptomatic
  • Positive results would recommend PCR confirmation (Isolate until results received)
  • Negative results taken at face value

• If symptomatic employee – shouldn’t be at work!
  • Get tested outside
  • Isolate until results received
  • Report results to workplace

• If symptomatic incoming inpatient
  • Positive results taken at face value – isolate and keep precautions in place
  • Negative results confirmed with PCR

• Must have strategy for follow-up PCR testing in place
Requesting BinaxNOW™ Ag Test Cards

• For additional test cards, complete and submit a BinaxNOW® Resource Request Form for Long Term Care Facilities (available at: https://ky.readyop.com/fs/4iY5/ac9d through 12/30/2020)

• KDPH staff will review and process resource requests daily

• KDPH will distribute test cards from the state warehouse and/or through UPS

KDPH Points of Contact

James R. House, Master Exercise Practitioner
State Health Operations Center Community Testing Operations Section Chief
Work Cell: (502) 330-5950
Email: jamesr.house@ky.gov

Robbie Hume
State Health Operations Center Logistics Section Chief
Work Cell: (502) 892-8899
Email: robbie.hume@ky.gov
Kentucky Health Information Exchange (KHIE) Portal


Charlese Blair, CRT, CMA, Project Coordinator, Office of Health Data and Analytics, Kentucky Health Information Exchange (KHIE)
Reporting Requirements

*Doug Thoroughman, PhD, MS, State Epidemiologist (Acting)*

*CDC Career Epidemiology Field Officer, Kentucky Department for Public Health*
Reporting Requirements

• All positive test results need to be reported
  • KHIE Portal or KHIE Electronic Lab Report feed
  • Clinical information reported separately if a clinical visit is involved
    • KDPH COVID-19 Case Investigation Form (Fillable)
    • https://khie.ky.gov/COVID-19/Pages/Direct-Lab.aspx

• All BinaxNOW Ag Test Cards utilized
  • Need to be reported in aggregate
    • Total tests performed each day
    • Total positive results each day
  • Online survey for this purpose
    • https://tinyurl.com/KyLabCovidAggRpt

• Who reports may vary depending on facility and scenario
Q/A and Points of Contact

**Surveillance, Testing and Reporting**

Doug Thoroughman, PhD, MS, State Epidemiologist (Acting), CDC Career Epidemiology Field Officer, KDPH
Phone: (502) 564-3418 x4315
Email: douglas.thoroughman@ky.gov

Kevin B. Spicer, MD, PhD, MPH, Medical Officer (CDC) Antibiotic Resistance Coordinator, HAI/AR Prevention Program, KDPH
Phone: (502) 564-3261 x4468
Email: kevin.spicer@ky.gov

**Logistics and Request Process**

James R. House, MEP, State Health Operations Center Community Testing Operations Section Chief, KDPH
Work Cell: (502) 330-5950
Email: jamesr.house@ky.gov

Robbie Hume, State Health Operations Center Logistics Chief, KDPH
Work Cell: (502) 892-8899
Email: robbie.hume@ky.gov

**Cabinet for Health and Family Services**

Keith Knapp, Senior Advisor, CHFS
Cell: (502) 229-3184
Email: keith.knapp@ky.gov

**Abbott**

Michelle Moran, Technical Consultant, Abbott Rapid Diagnostics
Cell: (502) 693-8829
Email: michelle.moran@abbott.com